Microbiome therapy · developed by Oragenics
Dapatifagene navolactibac is an oral rinse containing Lactococcus lactis bacteria genetically modified to secrete human trefoil factor 1 (hTFF1), a peptide normally secreted by mucous epithelia that helps protect and heal mucosal tissue. It is studied in oral mucositis, damage to the mouth lining caused by cancer therapies such as chemotherapy and radiation.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03234465 | Phase 2 | Oral Mucositis | Terminated | OGEN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Oral Mucositis
Updated Oct 25, 2026. Something wrong or missing? Report it on the OGEN page.
See OGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OGEN catalysts and pipeline →